DMPA and Intracranial Meningioma Risk: What Recent Research Means for Patients
A single contraceptive injection can be convenient for months. A brain tumour risk, even a rare one, can quickly make that convenience feel more complicated.
Recent research has raised a serious but nuanced question about depot medroxyprogesterone acetate, commonly known as DMPA, and the risk of intracranial meningioma. The finding does not mean everyone who has used the injection is in danger. It does mean patients and clinicians should discuss the duration of use, personal risk factors, and available alternatives with more care.
This article is for information only and is not a substitute for medical advice. Decisions about contraception, menstrual care, or hormone treatment should be made with a qualified healthcare professional.
What depot medroxyprogesterone acetate is used for
Depot medroxyprogesterone acetate is a long-acting progestogen injection. It is best known as a contraceptive injection given at regular intervals, usually every three months. In many settings, it is offered because it is private, does not require daily pill taking, and is highly effective when injections are taken on schedule.
Beyond contraception, medroxyprogesterone acetate may be used in selected cases for menstrual or gynaecological concerns. These can include heavy menstrual bleeding, painful periods, endometriosis-related symptoms, or situations where oestrogen-containing contraceptives are not suitable. Exact use varies by country, product licence, and clinical judgement.
The injection works mainly by:
Preventing ovulation
Thickening cervical mucus, which makes it harder for sperm to pass
Thinning the lining of the uterus
Its practical benefits are clear. It is long acting, discreet, and does not depend on daily adherence. For many patients, especially those who struggle with daily tablets or cannot use oestrogen, it can be a useful option.
The known side effects are also well recognised. These may include irregular bleeding, delayed return of fertility after stopping, weight changes in some people, mood changes, acne, headaches, and reduced bone mineral density with longer use. Clinicians often review ongoing use, especially when treatment continues for years.
The newer concern is different. It relates to meningioma, a tumour that forms from the meninges, the protective membranes around the brain and spinal cord.
What is an intracranial meningioma
An intracranial meningioma is a tumour that develops inside the skull from the meninges. Most meningiomas are non-cancerous, or benign, but “benign” does not always mean harmless. A tumour can press on the brain, optic nerves, blood vessels, or other sensitive structures.
Symptoms depend on size and location. Some meningiomas cause no symptoms and are found by chance during brain imaging. Others may cause:
Persistent or worsening headaches
Vision changes
Hearing problems
Seizures
Weakness or numbness
Problems with balance, memory, or speech
Treatment can range from monitoring with scans to surgery or radiotherapy. The decision depends on symptoms, growth, location, age, and overall health.
The interest in hormone-related risk is not new. Many meningiomas have hormone receptors, including progesterone receptors. Some are more common in women, and growth can sometimes be influenced by hormonal states or medicines. Stronger evidence already exists for certain high-dose progestogens, such as cyproterone acetate, being linked with meningioma risk. Recent work has widened the discussion to other progestogen medicines.
What recent research has found
The most discussed recent evidence comes from a large French national case-control study published in The BMJ in 2024. The researchers used national health data to compare people who had surgery for intracranial meningioma with matched controls who did not.
The study examined several progestogen medicines. It found that prolonged use of some progestogens was associated with an increased risk of intracranial meningioma. This included injectable medroxyprogesterone acetate.
The study authors concluded that “prolonged use of medroxyprogesterone acetate injection was associated with an increased risk of intracranial meningioma.”
That sentence is the key finding, but it needs context.
The study did not show that short-term exposure carries the same risk. It also did not prove that the medicine directly caused every tumour. Observational studies can show associations, but they cannot fully remove all other explanations. The strength of this study lies in its size, national data source, and focus on surgically treated meningioma. Its limits include the usual limits of database research, such as incomplete detail on symptoms, imaging, exact clinical reasoning, and individual risk factors.
A striking point from the French data was that the excess risk appeared linked to longer exposure. This matters because many patients use the contraceptive injection briefly, while others continue for several years.
The researchers also placed medroxyprogesterone acetate into a wider pattern. Other progestogens, including some already known to be associated with meningioma, showed signals as well. By contrast, not every progestogen studied showed the same level of concern. This suggests the risk may vary by molecule, dose, route, and duration.
Why hormones may be involved
The possible biological explanation centres on progesterone signalling. Many meningiomas express progesterone receptors. That means tumour cells may respond to progestogen activity, at least in some cases.
This does not mean every progestogen medicine will cause tumour growth. It also does not mean every meningioma is hormone driven. Brain tumours are complex, and individual risk varies. Age, sex, genetics, radiation exposure, and other health factors may all play a role.
Still, the hormone receptor evidence makes the epidemiological findings more plausible. When a study finds a link and there is a biological reason that could explain it, clinicians tend to take the signal more seriously.
The risk remains rare at an individual level. Meningioma itself is uncommon compared with the number of people who use hormonal contraception. The key question is not whether the injection is suddenly unsafe for everyone. The better question is who should avoid prolonged exposure, who needs a different option, and when a review is sensible.
What this means for patients considering the injection
For someone thinking about starting the contraceptive injection, the recent evidence should be part of counselling, not a reason for panic.
A useful discussion with a doctor should cover:
Why the injection is being considered
Expected duration of use
Past or current history of meningioma
Any neurological symptoms
Other contraceptive choices
Bone health, menstrual effects, and fertility plans
Personal preference and ability to use other methods reliably
Patients with a known meningioma, a previous meningioma, or unexplained neurological symptoms should tell their clinician before starting or continuing any progestogen treatment. In such cases, the clinician may recommend avoiding some hormonal options or seeking specialist advice.
For current users, stopping suddenly without a plan can lead to unintended pregnancy or return of symptoms that the medicine was controlling. A safer approach is to book a medication review. The clinician can help decide whether to continue, switch, or investigate symptoms.
Symptoms that deserve medical attention include new seizures, persistent headaches that are different from usual, progressive vision changes, unexplained weakness, or problems with speech or balance. These symptoms do not automatically mean meningioma, but they should not be ignored.
In India, contraceptive choice can be shaped by access, privacy, cost, family planning goals, and medical history. The same evidence-based principle applies nationwide: the best choice is the one that offers effective protection or symptom control with the lowest reasonable risk for that individual.
Weighing benefits against risks
The decision is rarely simple because the injection can solve real problems. For some patients, avoiding pregnancy is medically important. For others, heavy bleeding or endometriosis symptoms can affect daily life, work, education, and wellbeing.
A balanced view looks like this:
Potential benefits
Highly effective contraception when taken on schedule
Does not require daily tablets
Can be used by some people who cannot take oestrogen
May reduce menstrual bleeding or pain in selected patients
Potential concerns
Irregular bleeding is common, especially early on
Return to fertility may be delayed after stopping
Longer use can affect bone mineral density
Recent research suggests a possible increased meningioma risk with prolonged exposure
This is where duration becomes central. A short period of use after careful counselling may carry a different risk profile from use over many years. The French study’s signal was strongest around prolonged exposure, which supports regular review rather than passive continuation.
Alternative options may include copper intrauterine devices, levonorgestrel intrauterine systems, contraceptive implants, combined pills, progestogen-only pills, condoms, or permanent methods for those who have completed their family. Each has its own benefits and drawbacks. For menstrual conditions, non-contraceptive treatments may also be available, depending on the diagnosis.
There is no universally “best” method. There is only the most suitable method for a person’s medical history, preferences, risk tolerance, and reproductive plans.
What experts and clinicians are likely to do next
The recent findings are likely to influence prescribing conversations more than day-to-day emergency care. Clinicians may become more cautious about long-term use, especially where alternatives are acceptable.
Practical changes may include:
More detailed counselling before starting treatment
A clearer review point for ongoing users
Avoidance in patients with current or previous meningioma unless a specialist supports use
More attention to neurological symptoms during follow-up
Shared decision-making that includes rare but serious risks
Researchers will also need to clarify several questions. How long is too long? Does risk fall after stopping? Are some people more vulnerable than others? Does dose pattern or route change risk? Are findings from France similar in countries where use patterns differ?
The answers matter because injectable medroxyprogesterone acetate is used far more often in some countries than in France. A rare risk can have greater public health importance when many people are exposed.
The practical takeaway
Depot medroxyprogesterone acetate remains an effective and useful medicine for many people. Recent research does not erase its benefits, but it does add a meaningful caution about prolonged exposure and intracranial meningioma risk.
The most sensible response is not alarm. It is review.
Anyone considering the injection should ask how long they are likely to use it, what alternatives exist, and whether their medical history changes the risk. Anyone already using it long term should not stop without a plan, but should arrange a discussion with their healthcare provider.
The best decision is informed, individual, and revisited over time. That is especially true when a medicine is convenient enough to continue for years without much thought.
Comments